Head-To-Head Comparison: Enanta Pharmaceuticals (ENTA) & Global Blood Therapeutics (GBT)
Enanta Pharmaceuticals (NASDAQ: ENTA) and Global Blood Therapeutics (NASDAQ:GBT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, earnings and dividends.
Risk and Volatility
Enanta Pharmaceuticals has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Global Blood Therapeutics has a beta of 4.22, indicating that its share price is 322% more volatile than the S&P 500.
Valuation and Earnings
This table compares Enanta Pharmaceuticals and Global Blood Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Enanta Pharmaceuticals||$39.73 million||20.37||-$30.75 million||($1.07)||-39.62|
|Global Blood Therapeutics||N/A||N/A||-$95.43 million||($2.47)||-10.63|
Enanta Pharmaceuticals has higher revenue and earnings than Global Blood Therapeutics. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Global Blood Therapeutics, indicating that it is currently the more affordable of the two stocks.
This table compares Enanta Pharmaceuticals and Global Blood Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Global Blood Therapeutics||N/A||-38.92%||-36.49%|
Institutional and Insider Ownership
66.1% of Enanta Pharmaceuticals shares are held by institutional investors. Comparatively, 86.1% of Global Blood Therapeutics shares are held by institutional investors. 9.3% of Enanta Pharmaceuticals shares are held by insiders. Comparatively, 5.3% of Global Blood Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This is a summary of current recommendations for Enanta Pharmaceuticals and Global Blood Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Global Blood Therapeutics||0||0||12||0||3.00|
Enanta Pharmaceuticals currently has a consensus target price of $38.00, suggesting a potential downside of 10.36%. Global Blood Therapeutics has a consensus target price of $52.91, suggesting a potential upside of 101.54%. Given Global Blood Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Global Blood Therapeutics is more favorable than Enanta Pharmaceuticals.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305, which is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC, and EDP-938, which is a clinical candidate for RSV.
Global Blood Therapeutics Company Profile
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company’s GBT440 is an investigational drug that increases hemoglobin’s affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.
Receive News & Stock Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.